NasdaqCM:AHPI

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Allied Healthcare Products

Executive Summary

Allied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide.


Snowflake Analysis

Flawless balance sheet and slightly overvalued.

Share Price & News

How has Allied Healthcare Products's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: AHPI's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.5%

AHPI

-0.2%

US Medical Equipment

3.0%

US Market


1 Year Return

586.2%

AHPI

14.8%

US Medical Equipment

15.8%

US Market

Return vs Industry: AHPI exceeded the US Medical Equipment industry which returned 16.8% over the past year.

Return vs Market: AHPI exceeded the US Market which returned 15.4% over the past year.


Shareholder returns

AHPIIndustryMarket
7 Day0.5%-0.2%3.0%
30 Day-13.1%8.5%6.0%
90 Day-9.2%10.7%16.4%
1 Year586.2%586.2%15.8%14.8%18.4%15.8%
3 Year406.3%406.3%75.5%70.7%44.8%35.4%
5 Year259.7%259.7%118.0%101.1%75.7%56.7%

Price Volatility Vs. Market

How volatile is Allied Healthcare Products's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Allied Healthcare Products undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: AHPI ($10.43) is trading below our estimate of fair value ($71.31)

Significantly Below Fair Value: AHPI is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: AHPI is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: AHPI is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate AHPI's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: AHPI is overvalued based on its PB Ratio (4.4x) compared to the US Medical Equipment industry average (4.2x).


Next Steps

Future Growth

How is Allied Healthcare Products forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

27.6%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Allied Healthcare Products has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Allied Healthcare Products performed over the past 5 years?

-3.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: AHPI is currently unprofitable.

Growing Profit Margin: AHPI is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: AHPI is unprofitable, and losses have increased over the past 5 years at a rate of 3.9% per year.

Accelerating Growth: Unable to compare AHPI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AHPI is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1.2%).


Return on Equity

High ROE: AHPI has a negative Return on Equity (-31.33%), as it is currently unprofitable.


Next Steps

Financial Health

How is Allied Healthcare Products's financial position?


Financial Position Analysis

Short Term Liabilities: AHPI's short term assets ($12.0M) exceed its short term liabilities ($6.6M).

Long Term Liabilities: AHPI has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: AHPI is debt free.

Reducing Debt: AHPI had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable AHPI has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: AHPI is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 26.8% per year.


Next Steps

Dividend

What is Allied Healthcare Products's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate AHPI's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate AHPI's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if AHPI's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AHPI's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AHPI's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

15.2yrs

Average board tenure


CEO

Earl Refsland (77 yo)

20.92yrs

Tenure

US$502,491

Compensation

Mr. Earl R. Refsland has been the President and Chief Executive Officer at Allied Healthcare Products Inc. since September 1999. From May 1995 to March 1998, Mr. Refsland served as the President and Chief ...


CEO Compensation Analysis

Compensation vs Market: Earl's total compensation ($USD502.49K) is about average for companies of similar size in the US market ($USD606.98K).

Compensation vs Earnings: Earl's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Earl Refsland
CEO, President & Director20.92yrsUS$502.49k4.65%
$ 1.9m
John Weil
Independent Chairmanno dataUS$25.77k29.02%
$ 12.1m
Joseph Root
Independent Director13.83yrsUS$26.47k0.025%
$ 10.4k
Judith Graves
Independent Director16.5yrsUS$27.47k0.0062%
$ 2.6k
Susan Deuser
Independent Director0.67yrno datano data

15.2yrs

Average Tenure

76yo

Average Age

Experienced Board: AHPI's board of directors are seasoned and experienced ( 15.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: AHPI insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Allied Healthcare Products, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Allied Healthcare Products, Inc.
  • Ticker: AHPI
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$41.861m
  • Shares outstanding: 4.01m
  • Website: https://www.alliedhpi.com

Number of Employees


Location

  • Allied Healthcare Products, Inc.
  • 1720 Sublette Avenue
  • St. Louis
  • Missouri
  • 63110
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AHPINasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 1992

Biography

Allied Healthcare Products, Inc. manufactures and markets respiratory products for use in the health care industry in a range of hospitals and alternate site settings worldwide. The company offers respirat ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/08/07 01:36
End of Day Share Price2020/08/06 00:00
Earnings2020/03/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.